Aviir has launched two comprehensive genetic panels to test for undiagnosed arrhythmia or cardiomyopathy. The tests cover the major causes of cardiomyopathies, arrhythmia disorders, and other genetically transmitted diseases that affect the heart and vasculature. Each test is available for testing in both individual and familial settings.
Natera will now offer Panorma, its noninvasive sequencing-based test to screen for fetal aneuploidies, in Spain. The company is distributing the test through Echevarne, a clinical analysis laboratory in Spain. Natera first launched its test in the US in March.
WaferGen has launched SmartChip TE, a PCR-based target enrichment solution for sample preparation prior to targeted re-sequencing. The company said that the kit will be especially useful for clinical applications because it is based on proprietary technology that relies on massively parallel single-plex PCR reactions, where amplification is cleaner and better controlled, which will provide more accurate sequencing results.